Market Access
Inflation Reduction Act proves positive boost for biosimilars
For the pharma industry, the IRA has made headlines due to it …
19693 items found
Digital
AI and new technologies: How the pharmaceutical industry is reinventing itself to meet ever more urgent needs
The world is changing rapidly, and the healthcare sector is no …
News
Ono, Boehringer add to cancer pipelines with licensing deals
Ono Pharma and Boehringer Ingelheim both added to their cancer …
News
UK celeb seeks funds to challenge NICE's Enhertu verdict
UK actor and TV personality Nadia Sawalha is spearheading a …
News
City Therapeutics' $135m debut, and other bio financing news
Our round-up of recent biotech financings features a strong first …
News
Ex-Pfizer leaders side with firm against activist investor
Two former Pfizer executives drawn into a campaign by activist …
News
GSK says $2.2bn settlement resolves most Zantac litigation
GSK has reached an agreement that it says will resolve 93% of the …
Digital
Digital innovation and the Direct-To-Patient Model
Innovation is of no worth if it doesn’t provide better outcomes for …
Digital
Advancing Precision Care For All
Precision medicine is oft spoken about these days, as it is finally …
Sales & Marketing
Importance of choosing the right POC marketing partners in healthcare
With the fast-paced tech transformation of the healthcare marketing …
R&D
The future of multiple myeloma is personalised, but we must work together to deliver it
It’s true that we’ve come a long way in recent years when it comes to …
Sales & Marketing
Do HCPs really want the return of in-person meetings?
It is easy to assume that healthcare providers (HCPs) all want to go …
News
BenevolentAI CEO steps down as founders make a comeback
Jörg Möller's sojourn as chief executive of BenevolentAI has come to an abrupt end after just nine months, as the company names co-founder Ken Mulvany as its executive chairman.
Digital
Sponsored
Decoding physician prescribing behaviour: A data-driven jour...
Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Digital
Access to genomic surveillance: Open science and public heal...
The pandemic served as a catalyst for a revolution in genomic surveillance for tracking pathogens.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
